NasdaqCM - Delayed Quote • USD
ESSA Pharma Inc. (EPIX)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | -0.19 | -0.21 | -0.79 | -1.05 |
Low Estimate | -0.24 | -0.28 | -1 | -2.1 |
High Estimate | -0.15 | -0.15 | -0.6 | -0.61 |
Year Ago EPS | -0.16 | -0.17 | -0.6 | -0.79 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 3 | 4 | 3 |
Avg. Estimate | -- | -- | -- | -- |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | -- |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.2 | -0.19 | -0.21 | -0.17 |
EPS Actual | -0.16 | -0.17 | -0.12 | -0.14 |
Difference | 0.04 | 0.02 | 0.09 | 0.03 |
Surprise % | 20.00% | 10.50% | 42.90% | 17.60% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.19 | -0.21 | -0.79 | -1.05 |
7 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
30 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
60 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
90 Days Ago | -0.2 | -0.22 | -0.8 | -1.21 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | EPIX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -18.80% | -- | -- | 1.50% |
Next Qtr. | -23.50% | -- | -- | 12.10% |
Current Year | -31.70% | -- | -- | 4.40% |
Next Year | -32.90% | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Oppenheimer: Outperform to Outperform | 12/13/2023 |
Reiterates | Oppenheimer: Outperform to Outperform | 8/9/2023 |
Maintains | Piper Sandler: Overweight | 5/12/2022 |
Maintains | Oppenheimer: Outperform | 8/17/2021 |
Initiated | Piper Sandler: Overweight | 3/4/2021 |
Maintains | HC Wainwright & Co.: Buy | 2/25/2021 |
Related Tickers
MSCL.TO Satellos Bioscience Inc.
0.4400
-4.35%
MDNAF Medicenna Therapeutics Corp.
1.4000
+0.72%
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%
IRON Disc Medicine, Inc.
26.52
-2.86%
TRVI Trevi Therapeutics, Inc.
2.5400
-4.15%
ANVS Annovis Bio, Inc.
13.60
+6.75%
LUMO Lumos Pharma, Inc.
2.7600
-2.13%
SRZN Surrozen, Inc.
8.61
-3.69%
IMCR Immunocore Holdings plc
58.00
-0.80%
INAB IN8bio, Inc.
1.0400
-1.89%